You are here: Industry Insights > Cancer

News List

ICR study combines precision medicines to treat drug-resistant cancers pharmatimes
September 17, 2020
Results from an early-stage trial demonstrate that using a combination of two precision medicines to target hard-to-treat cancers was safe and showed promise in a range of solid tumour types.
SMC accepts 14 new medicines for use by NHS Scotland pharmatimes
September 17, 2020
Fourteen newly licensed medicines have been accepted for use on NHS Scotland by the Scottish Medicines Consortium (SMC), bringing a raft of new treatment options for conditions including epilepsy, depression and cancer.
Seattle Genetics and Merck Partner contractpharma
September 15, 2020
Seattle Genetics Inc. and Merck, known as MSD outside the United States and Canada, have announced two new strategic oncology collaborations.
Research backs use of liquid biopsy for personalised cancer care pharmatimes
September 14, 2020
UK research has shown that a blood test is able to identify various mutations in advanced breast cancer and can thus match women to targeted treatment, adding further weight to evidence backing use of liquid biopsies for more personalised cancer care.
AbbVie, I-Mab Enter Global Immuno-Oncology Alliance contractpharma
September 07, 2020
AbbVie to pay as much as $1.74 billion for Lemzoparlimab, one of I-Mab's leading drug candidates for the treatment of multiple cancers.
Rain Therapeutics Licenses MDM2 Inhibitor from Daiichi Sankyo contractpharma
September 03, 2020
DS-3032 has been evaluated in clinical trials for solid tumors and hematologic malignancies.
Bayer invests in cancer therapies developer Triumvira Immunologics pharmaceutical-technology
August 31, 2020
Bayer’s investment unit Leaps by Bayer and Northpond Ventures led the $55m Series A funding round of cancer therapies developer Triumvira Immunologics.
Researchers develop technology to see inside cells expresspharma
August 21, 2020
The new technology may help answer outstanding questions about the immune system, cancer, Alzheimer’s, and more.
Gilead and Tango Therapeutics partner for targeted cancer therapies pharmaceutical-technology
August 19, 2020
Gilead Sciences has collaborated with Tango Therapeutics to discover, develop and commercialise targeted immune evasion therapies for cancer patients.
NHS adapts to pandemic with ‘COVID-friendly’ cancer treatments pharmatimes
August 05, 2020
NHS chief executive Sir Simon Stevens has announced plans for a £160m initiative to roll-out ‘COVID-friendly’ cancer treatments for patients across the UK.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page